AI
ANRis, Inc.
Japan · Biotech
A biotechnology company developing siRNA medicines designed to suppress disease-causing mutations while preserving normal gene function.
Distinguishing a mutant gene from its normal counterpart
ANRis develops SNPD-siRNA, a sequence-design technology intended to distinguish genes that differ by a single nucleotide. Its approach aims to silence the disease-causing version while sparing the corresponding normal gene.
The Tokyo company is focusing its early drug-candidate and preclinical work on KRAS-mutant cancers. Alongside sequence design, it is researching delivery systems and formulations to get the siRNA into target tissue, drawing on university research behind the platform.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Funding | ~¥220M | Japan Science and Technology Agency — ParticipantWaseda University Ventures Co., Ltd. — Participant |